

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
December 1, 2004
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, December 1, 2004.

2. Welcome

Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Chairperson LaCroix thanked the Pharmacy Association for again providing their building as the meeting place for the P&T Committee. Also, appreciation was expressed to the Pharmacy Association for providing refreshments for the P&T Committee members.

Dr. LaCroix noted that there were several absences due to vacations and other commitments. The P&T Committee was informed of the resignations of Dr. Weart and Dr. Lucas.

Chairperson LaCroix welcomed ophthalmologists, Dr. Richard Davis and Dr. Joshua Frankel, to the meeting. Drs. Davis and Frankel provided consultant services to the P&T Committee for ophthalmic products considered for the PDL.

Committee Members Present:

J. Kevin Baugh, M.D.	James M. Lindsey, M.D.
Matthew K. Cline, M.D.	Mark A. O'Rourke, M.D.
Joseph A. Horvath, M.D.	Thomas Phillips, R.Ph.
Albert Humphrey, M.D.	George E. Vess, Pharm.D.
Robin K. LaCroix, M.D.	

Committee Members Absent:

Edward M. Behling, M.D.	Deborah J. Tapley, R.Ph.
Jerome E. Kurent, M.D.	Harry H. Wright, M.D.

	Company	Speaker	Drug
5)	Schering-Plough	Randy Pryka, Pharm.D., Clinical Science Specialist-Anti-Infectives, Scientific Affairs, Bayer Corp, Adjunct Assoc Professor of Clinical Pharmacy, Univ of Toledo College of Pharmacy	Cipro XR®, Avelox®
6)	Pfizer	Cherie A. Lovelace, Pharm.D., Sr. Regional Medical & Research Specialist, Pfizer, Inc.	Xalatan®
7)	Merck	Myles Jaffe, O.D., Ph.D., Mgr, Medical Services, Merck & Co., Medical & Scientific Affairs	Cosopt®, Trusopt®
8)	Boehringer-Ingelheim	Sarkis Steven Derderian, M.D., Internal Medicine, Pulmonary Medicine, Sleep Medicine, Columbia, SC	Spiriva®
9)	Roche	Peter M. Suresky, Pharm.D., Oncology Medical Liaison, Roche Laboratories	Kytril®
10)	Schering Plough	Eddie Dowling, Schering Plough Representative	PEG-Intron®

Following the period of public comment, Dr. LaCroix thanked each speaker for his or her individual presentation.

D. PDL Discussions And Selections For The Following Drug Classes

Mary Roberts, R.Ph., First Health Corporation led the discussion for the following drug classes:

- 1) Glaucoma Agents
 - ◆ Alpha 2 Adrenergic Agents
 - ◆ Beta Blockers
 - ◆ Carbonic Anhydrase Inhibitor
 - ◆ Prostaglandin Agonist
- 2) Anti-Emetics: 5-HT₃ Receptor Antagonists
- 3) Anticholinergics: COPD Therapy
- 4) Antibiotics: Quinolones, Second & Third Generation
- 5) Antibiotics: Macrolides / Ketolides
- 6) Pegylated Interferons
- 7) Ribavirins, Oral

The P&T Committee agreed to submit the following recommendations to DHHS:

No PA Required "Preferred"	PA Required
GLAUCOMA AGENTS ALPHA 2 ADRENERGIC AGENTS	
Brimonidine Tartrate	Alphagan® (discontinued by manufacturer) Alphagan P® Iopidine®
The P&T Committee agreed that grandfathering of these agents should be permitted.	
GLAUCOMA AGENTS BETA BLOCKERS	
Betaxolol HCl Carteolol HCl Levobunolol HCl Metipranolol Timolol Maleate Timolol Maleate gel-forming	Betagan® Betimol® Betoptic S® Ocupress® Optipranolol® Timoptic® Timoptic-XE®
The P&T Committee agreed that grandfathering of these agents should be permitted.	
GLAUCOMA AGENTS CARBONIC ANHYDRASE INHIBITORS	
Azopt® Cosopt® Trusopt®	
The P&T Committee agreed that grandfathering of these agents should be permitted.	
GLAUCOMA AGENTS PROSTAGLANDIN AGONISTS	
Lumigan® Xalatan®	Rescula ® (to be discontinued) Travatan®
The P&T Committee agreed that grandfathering of these agents should be permitted.	
ANTI-EMETICS 5-HT₃ RECEPTOR ANTAGONISTS	
Kytril® Zofran® Zofran ODT®	Anzemet®
ANTICHOLINERGICS COPD THERAPY	
Atrovent® Combivent® Spiriva®	

No PA Required "Preferred"	PA Required
ANTIBIOTICS QUINOLONES: SECOND AND THIRD GENERATION	
Ciprofloxacin Levaquin® Ofloxacin Tequin®	Avelox® Avelox ABC Pack® Cipro® Cipro Suspension® Cipro XR® Floxin® Maxaquin® Noroxin® Zagam®
ANTIBIOTICS MACROLIDES / KETOLIDES	
Biaxin® Biaxin XL® EryPed® Ery-Tab® Erythromycin Base Erythromycin Estolate Erythromycin Ethylsuccinate Erythromycin Stearate Erythrocin Stearate Erythromycin w/ Sulfisoxazole Zithromax®	Dynabac® Eryc® EES® Ketek® PCE® Pediazole® Tao®
PEGYLATED INTERFERONS	
Pegasys® and Conv. Pack PEG-Intron® and Redipen	
RIBAVIRINS, ORAL	
Copegus® Rebetol®	Ribasphere® Ribavirin®

6. Old Business

Prior Authorization Criteria

The Committee approved the PA Criteria document for Phases 1, 2, and 3.

7. **New Business**

A. Selection/Designation of Drug Classes for PDL Formulary

The following drug classes were presented as classes for potential discussion at the February 2, 2005 meeting:

Alzheimer's Agents
Herpes Antivirals
Onychomycosis Antifungals
Topical Immunomodulators
Urinary Tract Antispasmodics

B. Michael J. Bykowsky, M.D.

Dr. Bykowsky spoke to the P&T Committee about the prior authorization process. He discussed the fact that primary care physicians refer many patients to him since he is a specialist. As a result, most of Dr. Bykowsky's patients have previously tried preferred therapy (such as loratadine) by the patients' primary physicians. He suggested that board-certified allergists be exempt from PA requirements. Dr. Bykowsky discussed the impact of the PDL upon products such as Zyrtec® and Allegra®. He offered to assist the P&T Committee when products frequently prescribed by allergists are re-reviewed.

C. Ms. Brande M. Smalley

Ms. Smalley addressed the P&T Committee about her concerns regarding beneficiary notification of drugs requiring prior authorization. She discussed the need for beneficiaries, physicians, and pharmacists to be continually updated on the prior authorization process and the coverage policies of drugs.

D. Presentations at P&T Committee Meetings

Dr. Horvath discussed the current format of pharmaceutical manufacturers asking individuals to give brief speeches on specific drugs for PDL consideration. The P&T Committee members discussed various options to ensure that presentations are beneficial and informative.

8. **Resolved Items**

Recommendations regarding PDL status for drugs in the following drug classes were approved for submission to DHHS:

Glaucoma Agents
◆ Alpha 2 Adrenergic Agents
◆ Beta Blockers
◆ Carbonic Anhydrase Inhibitor
◆ Prostaglandin Agonist
Anti-Emetics: 5-HT₃ Receptor Antagonists
Anticholinergics: COPD Therapy
Antibiotics: Quinolones, Second & Third Generation
Antibiotics: Macrolides / Ketolides
Pegylated Interferons
Ribavirins, Oral

9. Unresolved Items

None.

10. Closing Comments

Dr. LaCroix thanked the Pharmacy Association for hosting the P&T Committee meeting and announced that the next P&T Committee meeting will be held on February 2, 2005.

11. Adjournment

The meeting adjourned at 7:00 p.m.